Literature DB >> 15145452

Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge.

Mark A Chambers1, Dolores Gavier-Widén, R Glyn Hewinson.   

Abstract

Tuberculosis caused by infection with Mycobacterium tuberculosis or Mycobacterium bovis is a significant disease of man and animals. Whilst cellular immunity is the major immunological component required for protection against these organisms, recent reports have suggested that monoclonal antibodies can modify infection with M. tuberculosis. To test whether the same was true for M. bovis infection, we determined the effect of preincubation of M. bovis with a monoclonal antibody on subsequent intravenous infection of mice. Antibodies bound to the surface of M. bovis increased the survival time of mice infected with M. bovis and changed the morphology of granulomas and the distribution of acid-fast bacilli in the lung. These studies suggest that antibodies directed to the surface of virulent mycobacteria can modulate their virulence in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145452     DOI: 10.1016/j.femsim.2004.01.004

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  21 in total

Review 1.  Do CD1-restricted T cells contribute to antibody-mediated immunity against Mycobacterium tuberculosis?

Authors:  Mark L Lang; Aharona Glatman-Freedman
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

Review 2.  The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

Authors:  John Chan; Simren Mehta; Sushma Bharrhan; Yong Chen; Jacqueline M Achkar; Arturo Casadevall; JoAnne Flynn
Journal:  Semin Immunol       Date:  2014-10-28       Impact factor: 11.130

Review 3.  Th1 cytokines, true functional signatures for protective immunity against TB?

Authors:  Gucheng Zeng; Guoliang Zhang; Xinchun Chen
Journal:  Cell Mol Immunol       Date:  2017-11-20       Impact factor: 11.530

4.  Peripheral blood and pleural fluid mononuclear cell responses to low-molecular-mass secretory polypeptides of Mycobacterium tuberculosis in human models of immunity to tuberculosis.

Authors:  Suraj B Sable; Rajnish Kumar; Mamta Kalra; Indu Verma; G K Khuller; Karen Dobos; John T Belisle
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 5.  Antibody-mediated immunity against tuberculosis: implications for vaccine development.

Authors:  Jacqueline M Achkar; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

6.  Antibody responses of cervids (Cervus elaphus) following experimental Mycobacterium bovis infection and the implications for immunodiagnosis.

Authors:  Noel P Harrington; Om P Surujballi; John F Prescott; J Robert Duncan; W Ray Waters; Konstantin Lyashchenko; Rena Greenwald
Journal:  Clin Vaccine Immunol       Date:  2008-09-24

Review 7.  The protective role of antibody responses during Mycobacterium tuberculosis infection.

Authors:  F Abebe; G Bjune
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

8.  Intranasal IFNgamma extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection.

Authors:  R Reljic; S O Clark; A Williams; G Falero-Diaz; M Singh; S Challacombe; P D Marsh; J Ivanyi
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

9.  Determinants of natural immunity against tuberculosis in an endemic setting: factors operating at the level of macrophage-Mycobacterium tuberculosis interaction.

Authors:  A N Gaikwad; Sudhir Sinha
Journal:  Clin Exp Immunol       Date:  2008-03       Impact factor: 4.330

10.  Monoclonal antibodies to Mycobacterium tuberculosis CDC 1551 reveal subcellular localization of MPT51.

Authors:  Ban Al-Sayyed; Sajida Piperdi; Xinni Yuan; Anping Li; Gurdyal S Besra; William R Jacobs; Arturo Casadevall; Aharona Glatman-Freedman
Journal:  Tuberculosis (Edinb)       Date:  2007-09-19       Impact factor: 3.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.